Massachusetts-based Satio, Inc. recently announced a commercially viable intradermal microneedle drug delivery device designed for home use. The project that developed this device is part of ARPA-H’s Small Business Innovation Research (SBIR) initiative to propel high-impact biomedical research and development from U.S. small businesses.
According to the agency and company Digital SatioRx, is a low-cost, remotely controllable, disposable microneedle intradermal drug delivery device able to deliver any FDA-approved, liquid intradermal drug to a patient instantaneously. Digital SatioRx is telehealth-enabled and remotely mirrors an in-office visit, allowing health care providers to safeguard patient compliance while reducing costs and shifting care to the home. The device’s delivery system combines emerging technologies including easy application, telehealth and electronic health record integration, intradermal dosing using hollow non-dissolving microneedles that avoid pain receptors, and a cost-effective reusable injector.
The Commonwealth is home to ARPA-H’s Investor Catalyst Hub. Massachusetts-based companies and institutions have been awarded approximately more than $400 million through ARPA-H. Read more via Satio and ARPA-H.
